A new approach to protein degradation
Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.
Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.
CEO Antony Mattessich
Advent Contact Dominic Schmidt
Advent founded and seeded Amphista in 2018.
Private Companies
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
Press Release. Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer 3 September 2024 The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted…
Read More
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
Press Release. Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium 23 May 2024 First presentation of a novel mechanism…
Read More
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
Press Release. Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First demonstration of efficacy in disease-relevant in…
Read More
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Press Release. PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company”…
Read More
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
Press Release. Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb 4 May 2023 CAMBRIDGE, UK, May 4, 2023 - Amphista Therapeutics, a leader in next…
Read More
Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022
Press Release. Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it…
Read More
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release. Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39…
Read More
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release. Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment…
Read More
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Press Release. Amphista Therapeutics Appoints Dr Martin Pass as CDO Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today…
Read More
Amphista Therapeutics Appoints CBO, Beverley Carr
Press Release. Amphista Therapeutics Appoints CBO, Beverley Carr Cambridge, England, 1 November 2021 - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the…
Read More
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Press Release. Glasgow, UK, 21 September 2021 - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as…
Read More
Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
Press Release. Glasgow, Scotland, 28 June 2021 - Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove…
Read More
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release. Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company Glasgow, UK, 17 March 2021 - Amphista Therapeutics, a leader…
Read More
Amphista Therapeutics appoints leading protein degradation pioneer, Ian Churcher as CSO
Press Release. Glasgow, Scotland, 21 May 2020 - Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively…
Read More
Amphista Therapeutics raises $7.5m Series A round to advance targeted protein degradation assets in cancer
Press Release. April 7, 2020 Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based…
Read More
